Sopha Medical Systems' short-lived effort to expand into the U.S.MRI market is about to come to an end. The nuclear camera andcomputer vendor's parent company is close to completing a dealto shed the MRI venture, according to Buster Houchins, vice
Sopha Medical Systems' short-lived effort to expand into the U.S.MRI market is about to come to an end. The nuclear camera andcomputer vendor's parent company is close to completing a dealto shed the MRI venture, according to Buster Houchins, vice presidentof sales.
Sopha Medical of Buc, France, acquired French MRI developerMagnetech in 1991 by purchasing a 51% share of the company (SCAN5/22/91).
Sopha had plans for a U.S. introduction of Magnetech's 0.1-teslascanner, dubbed Sophymag, and displayed the unit at the 1992 meetingof the Radiological Society of North America. Magnetech was subsequentlyrenamed Sopha Imaging.
Softness in the global MRI market derailed Sopha's plans tobecome an MRI contender, however.
Sopha transferred its interest in Sopha Imaging to parent CEA-Industrieafter a controlling interest in Sopha was purchased by that divisionof the French government's Atomic Energy Commission (SCAN 4/7/93).
CEA-I shortly thereafter began exploring its options for theMRI subsidiary (SCAN 9/8/93). Some of those options included takingbids from buyers interested in purchasing Sopha Imaging.
That process is nearly complete and CEA-I is in the final stagesof negotiations with an unnamed buyer, according to Houchins.The sale should be completed by the end of November and an announcementwill probably be made at this year's RSNA meeting.
"We've decided to focus on nuclear medicine," Houchinssaid.
Six Sophymag scanners have been installed in Europe, accordingto Houchins.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.